SYNOPSIs The differential ferrioxamine test is a simple method for the measurement of chelation of body iron by desferrioxamine. A single six-hour specimen of urine is obtained after intravenous Desferal, accompanied by 59Fe-ferrioxamine. Two values are measured: Fd, the excretion of ferrioxamine derived from body iron by chelation, and Fex, the proportion of ferrioxamine excreted from a known intravenous dose. The data enables F,, chelation of iron in vivo, to be calculated by simple proportion. Desferrioxamine chelation proceeds for about half an hour after injection.
The clinical assessment of the state of the body iron is made by indirect methods, which include haemoglobin concentration, mean corpuscular haemoglobin concentration, examination of the stained blood film, serum iron concentration, and the amount of iron-binding globulin, transferrin. There is a considerable literature dealing with the interrelationships of these parameters and their interpretation (see, for instance, Beutler, Fairbanks, and Fahey, 1963; Harris, 1963) . In some situations the interpretation of these investigations taken together is unmistakable: in severe iron deficiency, for instance, a characteristic pattern of results is obtained. Nevertheless, these measurements are subject to many influences such as infection, neoplasm, renal failure, and metabolic disorders, which affect their values apart from iron status, and in such conditions interpretation may be speculative. Furthermore, they are of minor importance in the diagnosis of iron storage diseases.
A more direct approach to assessing storage iron may be by needle biopsy of the marrow, staining the aspirated material for ferritin and haemosiderin by the prussian blue reaction (Rath and Finch, 1948) .
Received for publication 28 September 1964. As a guide to iron deficiency, marrow puncture is especially useful, although the concentration of ferritin must attain certain minimal levels before it becomes visible by this staining method (Shoden and Sturgeon, 1960) . The rare but classic case of atransferrinaemia (Heilmeyer, Keller, Vivell, Keiderling, Betke, W6hler, and Schultze, 1961) showed that marrow iron does not necessarily reflect total iron stores: the marrow was entirely devoid of nonhaem iron and the liver and spleen were overloaded with iron. In pulmonary and in renal haemosiderosis marrow iron may be entirely absent; in haemochromatosis there is a proportionally smaller increase in iron in the marrow than in the liver and the pancreas; in haemosiderosis the marrow receives a relatively greater proportion of the iron overload than in haemochromatosis. Prussian-blue-reacting iron may often be irregularly distributed in marrow, a finding which may be appreciated when the aspirated material contains many cellular marrow granules. There is room, therefore, for some doubt when the aspirated specimen contains only a few small granules.
Liver puncture is an important method of assessing iron storage disease and their differential diagnosis Differential ferrioxamine test for measuring chelatable body iron (Williams, Scheuer, and Sherlock, 1962 ), but does not commend itself to wide application in the study of iron stores. Moreover, there are few data on the correlation between chemical assay of liver iron and histochemical appearances.
Body iron stores have also been measured by experimental methods. Hynes (1949) removed a small volume of blood each day for many months until the onset of iron-deficiency anaemia; larger amounts of blood have been withdrawn by venesecttion until the subject fails to make a spontaneous recovery to the induced anaemia (Haskins, Stevens, Finch, and Finch, 1952) . Radio-isotope dilution techniques have also been used: these require some weeks of observation and give results lower than after phlebotomy since much of the storage iron fails to exchange with the isotope (Finch, 1959) . Chelating agents with strong iron affinity have been used: Korman (1960) used 59Fe-EDDHA as an isotope dilution technique and claimed to distinguish iron deficiency, renal anaemia, and the anaemia of infection. Post-mortem assays of non-haem iron have also been made (Morgan and Waters, 1963) .
Desferrioxamine B (Desferal, Ciba) is a powerful and specific chelator of trivalent iron, forming the ferric chelate, ferrioxamine B ( occurs in vivo and ferrioxamine is excreted in the urine. The highly specific affinity for iron has suggested the use of desferrioxamine to increase iron excretion in haemochromatosis, in other forms of siderosis, and to bind iron in the treatment of acute poisoning (Moeschlin, 1962) . A further use for desferrioxamine has been suggested (Keberle, 1964) , as a screening test for iron-storage disease by measuring the increase in urinary iron after an intramuscular injection of the chelator. (Hallberg, 1964; Ventura, 1964) . The method described here is based on chelation of body iron by desferrioxamine. Urinary iron is measured as ferrioxamine, and the proportion of ferrioxamine excreted in the urine is measured isotopically. Thus the amount of chelation in vivo may be calculated. The method is applicable to conditions of both high and low iron stores. The object of the present paper is primarily to describe the method but it will also be shown that a readily chelatable form of iron occurs in haemolytic anaemias.
PRELIMINARY INVESTIGATION OF THE URINARY EXCRETION OF FERRIOXAMINE
It has been reported (Wohler, 1962 ) that all ferrioxamine given by intramuscular or intravenous injection appears in the urine. If this were so, urinary ferrioxamine (or urinary iron) could be used as a measure of body iron chelation by desferrioxamine. However, utilization of ferrioxamine iron for haemoglobin synthesis has also been reported (Bannerman, Callender, and Williams, 1962) which implies retention of a proportion of the ferrioxamine and so invalidates urinary iron as a direct measure of chelation. The point was therefore reinvestigated. After an intravenous injection of ferrioxamine the proportion excreted in the urine of normal subjects is in the range of about 50 to 70% of the dose in 72 hours (Fig. 2 ). In haematological disorders this The excretion of ferrioxamine in six hours is a consistent fraction of total excretion. Figure 3 shows six-hour ferrioxamine excretion following an intravenous dose. In normal subjects about 30 to 50% of the dose is excreted in six hours; in iron-deficiency anaemias about half the cases excrete a lesser proportion of ferrioxamine than normal subjects; in haemolytic anaemia and untreated pernicious anaemia excretion is invariably low; it is low also in aplastic anaemia, in leukaemia, and in some polycythaemias. In three cases of haemochromatosis the proportion of the dose excreted was in the normal range. In a case of erythrogenesis imperfecta, with transfusional haemosiderosis, 90% of the dose was excreted in six hours. Ferrioxamine excretion thus varies widely from case to case; it varies also at different stages of disease in the same subject.
It follows from these observations that when desferrioxamine chelates body iron to form ferrioxamine, the amount of ferrioxamine (or of When a standard body weight dose of ferrioxamine labelled with 59Fe-ferrioxamine is injected intravenously, the proportion of isotope excreted in the urine is the same as the proportion of chemically estimated ferrioxamine (Fielding, 1964) . This is so whether body iron stores are high, as in haemochromatosis, or absent, as in iron-deficient subjects. It follows that no exchange takes place between iron as ferrioxamine and other body iron. The excretion of the isotope may therefore be used to monitor the excretion of injected ferrioxamine.
THE DIFFERENTIAL FERRIOXAMINE TEST PRINCIPLE An intravenous injection is given consisting of two components: (1) a dose of desferrioxamine calculated according to body weight, and (2) a dose of ferrioxamine labelled with approximately 2 zC Fe-9 also calculated according to body weight. The urinary excretion of injected ferrioxamine is measured by isotope assay. Total ferrioxamine excretion is assayed chemically: this is derived from injected ferrioxamine plus that formed from body iron by desferrioxamine. The Figure 4 shows the pattern of results obtained in a normal subject. Ft is the amount of ferrioxamine excretion estimated chemically and derives from both ferrioxamine injected and from chelation in vivo. Fex, estimated isotopically, is the ferrioxamine excretion derived from the intravenous dose of ferrioxamine. The difference, Fd, is the ferrioxamine excretion derived from chelation in vivo. Figure 5 shows the variable pattern of results obtained in a normal subject, in an iron-deficient subject, in a case of pernicious anaemia, and in a case of aplastic anaemia; in Fig. 6 , on a smaller ordinate scale, the results in a case of untreated haemochromatosis, in a normal subject, and in a further case of severe iron-deficiency anaemia. These cases illustrate the variability found in both absolute and relative amounts of ferrioxamine formed in vivo and the proportion excreted in the urine.
EXCRETION OF CHELATED AND OF INJECTED FERRIOX-
AMINE In order to deduce the amount of chelation in vivo from the excretion of injected ferrioxamine, it must be shown that both sources of ferrioxamine follow similar metabolic pathways. Figure 7 shows that there is a linear relationship between the excretion of the two sources of ferrioxamine from the first observation at two hours, up to periods of 21 hours, in varying clinical states. Once chelation has reached its maximum, urinary excretion of the two sources of ferrioxamine follow each other closely and it is therefore reasonable to assume their metabolic behaviour is identical. Extrapolation of the graphs is not through the origin, since some time delay must occur in the formation of Fd by chelation. It is clear, however, that chelaton is maximal in less than two hours.
CHELATION TIME The chelator, desferrioxamine, is partly excreted in the urine and partly destroyed enzymatically in the plasma (Peters, 1964 reading. occurs first, since it is injected, and zero Fd which is delayed, since it is formed by chelation. The difference in the zero intercepts indicates the time difference between injection and chelate formation, on the theoretical assumption that all chelation takes place at a given moment some time after injection. In all three conditions chelation time appears to be about half an hour. A similar order of time has been found in other conditions analysed in this way: it seems evident that the time of formation of ferriox- Figure 9 shows the results in conditions with expected iron stores above normal. In the first column are normal subjects, with Figure 10 shows the results in established iron deficiency among patients with haemoglobin less than lOg. %, with low serum iron levels and serum transferrin saturation less than 15 %, all of whom subsequently responded to iron therapy. The range in normal subjects is shown in the left column. In 26 of 31 cases, Fv was below the normal range. In five cases iron chelation was within the normal range. These findings are discussed below. after injection of a chelator to indicate iron store status contains two assumptions. First, that the amount of chelate formed in vivo is proportional to iron stores: this will be considered below. Second, that the amount of chelate excreted is a measure of the amount formed in vivo. In the case of ferrioxamine, the proportion of an intravenous dose which later appears in the urine varies widely from case to case and at different stages of the same disorder. Consequently urinary ferrioxamine excretion does not directly measure the amount of ferrioxamine formed from its chelator. Additional information is required to interpret the amount formed in terms of the amount excreted.
The method of obtaining this information in the test depends on three characteristics of desferrioxamine-ferrioxamine chelation.
1
The iron in ferrioxamine does not exchange with other body iron. When ferrioxamine is injected accompanied by a label of Fe59 ferrioxamine, the proportion of isotope excreted is the same as that of chemically determined ferrioxamine (if exchange took place the proportion of isotope would be lower). This has been demonstrated when iron stores are high as in haemochromatosis and in haemolytic anaemia, in normals, and in irondeficient subjects (Fielding, 1964) . The excretion of isotope has therefore been used to monitor the excretion of injected ferrioxamine.
2 There is a linear relationship between the excretion of chelated in vivo (Fd) and injected (Fex) ferrioxamine from the first observation at two hours up to periods of 21 hours. It may be assumed, therefore, that ferrioxamine chelated from body iron behaves metabolically in the same way as injected ferrioxamine; it also means that maximuim chelation has been achieved in less than two hours.
These characteristics permit chelation in vivo (Fv) to be calculated by simple proportion: Fv= -F Fex mg., and the result is expressed as micrograms per kilogram body weight. In this expression F/weight is the dose of ferrioxamine given and is constant. Thus Fv depends upon the ratio FdIFex. This confers certain useful features on the method: Fd/Fex is a linear function and if chelation were instantaneous, the graph Fd/Fex would pass through the origin (Fig. 7) and there would be no zero intercept difference on the time base (Fig. 8) ; the ratio Fd/Fex would be entirely independent of time. In fact the ratio rises slightly between two and six hours and is for practical purposes constant thereafter. The timing of urine specimens is thus not critical above six hours, and the same result is obtained from a six-or a seven-hour specimen.
The ratio is independent of renal function, since both terms of the ratio are equally affected by variations in renal function. Gross renal insufficiency places a limitation on the test in that sufficient ferrioxamine must be excreted to make accurate chemical assay possible.
The ratio is independent of minor losses in urine collection, since both terms of the ratio are again equally affected by such loss.
These characteristics contribute to the sensitivity and reproducibility of the procedure.
In order to validate and obtain data for the interpretation of the test, the technique has been applied in clinical situations where iron status could reasonably be inferred from other data. 
